Article
Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination
Registro en:
REZENDE, Izabela Maurício et al. Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination. Vaccines, v. 7, n. 4, 206, 2019
2076-393X
10.3390/vaccines7040206
Autor
Rezende, Izabela Maurício de
Alves, Pedro Augusto
Arruda, Matheus Soares
Gonçalves, Andreza Parreiras
Oliveira, Gabriela Fernanda Garcia
Pereira, Leonardo Soares
Dutra, Maria Rita Teixeira
Azevedo, Ana Carolina Campi
Valim, Valéria
Tourinho, Renata
Oliveira, Jaquelline Germano de
Calzavara, Carlos Eduardo
Said, Rodrigo Fabiano do Carmo
Kroon, Erna Geessien
Martins Filho, Olindo Assis
Carvalho, Andrea Teixeira de
Drumond, Betânia Paiva
Resumen
The yellow fever (YF) vaccine consists of an attenuated virus, and despite its relative
safety, some adverse events following YF vaccination have been described. At the end of 2016, Brazil experienced the most massive sylvatic yellow fever outbreak over the last 70 years and an intense campaign of YF vaccination occurred in Minas Gerais state in Southeast Brazil from 2016 to 2018. The present study aimed to develop a genotyping tool and investigate 21 cases of suspected adverse events following YF vaccination. Initial in silico analyses were performed using partial NS5 nucleotide sequences to verify the discriminatory potential between wild-type and vaccine viruses. Samples from patients were screened for the presence of the YFV RNA, using 50UTR as the target, and then used for amplification of partial NS5 gene amplification, sequencing, and phylogenetic analysis. Genotyping indicated that 17 suspected cases were infected by the wild-type yellow fever virus, but four cases remained inconclusive. The genotyping tool was e_cient in distinguishing the vaccine from wild-type virus, and it has the potential to be used for the di_erentiation of all yellow fever virus genotypes.